Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target.

Autor: Richard, François, De Schepper, Maxim, Maetens, Marion, Leduc, Sophia, Isnaldi, Edoardo, Geukens, Tatjana, Van Baelen, Karen, Nguyen, Ha-Linh, Vermeulen, Peter, Van Laere, Steven, Bertucci, François, Ueno, Naoto, Dirix, Luc, Floris, Giuseppe, Biganzoli, Elia, Desmedt, Christine
Předmět:
Zdroj: Breast; Jun2023, Vol. 69, p476-480, 5p
Abstrakt: Inflammatory breast cancer (IBC) is a rare but aggressive subtype of breast cancer, mainly characterized using primary tumor samples. Here, using public datasets, we compared the genomic alterations in primary and metastatic samples from patients with metastatic IBC versus patients with metastatic non-IBC. We observed a higher frequency of AURKA amplification in IBC. We further showed that AURKA amplification was associated with increased AURKA mRNA expression, which we demonstrated was higher in IBC. Finally, higher protein expression of AURKA was associated with worse prognosis in patients with IBC. These findings deserve further investigation given the existence of AURKA-inhibitors. • Inflammatory breast cancer (IBC) is a rare understudied but aggressive type of breast cancer. • AURKA amplification appeared to be more common in patients with metastatic IBC as compared to non-IBC. • AURKA amplification is associated with AURKA expression. • AURKA protein expression is associated with worse prognosis in patients with IBC. [ABSTRACT FROM AUTHOR]
Databáze: Supplemental Index
Externí odkaz: